Mittwoch, 23. Mai | 21:44 Uhr

DJ EANS-Adhoc: Epigenomics AG / Ad hoc (§15 WpHG): Epigenomics AG: Notice of Loss

=-------------------------------------------------------------------------------
  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
=------------------------------------------------------------------------------- 

25.03.2009 

Berlin, Germany, - The Executive Board of Epigenomics AG notifies that using its
due diligence it has to be assumed that using German GAAP HGB) accounting losses
of more than half of the ordinary share capital have been incurred. In addition
to the anticipated operating losses in the first three months of the financial
year, a one-time effect not affecting liquidity has caused reaching this
threshold. This one-time effect does not have any implications on Epigenomics'
consolidated group financials under IFRS. 

In agreement with § 92 para. 1 AktG (German Stock Companies Act) the Executive
Board will summon without undue delay a general shareholder meeting to notify
all shareholders of the losses. The general meeting to be called will according
to current planning be combined with the Company's Annual  General Shareholders
Meeting 2009. The Annual General Shareholders Meeting 2009 will be held on May
11, 2009, 11:00 am CET at the premises of Deutsche Bank AG, Unter den Linden 13-
15 (Entrance Charlottenstraße), 10117 Berlin. 

End of Notification 

Further Information 

The Executive Board will be available for questions and further clarifying
statements during the regular annual press conference and analyst meeting 2009
that will be held on Tuesday, March 31, 2009 at 10 am to 12 noon CET at the
premises of the Villa Bonn - Frankfurter Gesellschaft für Handel Industrie und
Wirtschaft in Frankfurt am Main as well as during the regular earnings call at
3 pm on the same day (Dial-in number within Germany: +49 868 71 790; dial-in
number from outside Germany: +1 212 444 0297) 

Legal disclaimer 

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

end of announcement                               euro adhoc
=------------------------------------------------------------------------------- 

(END) Dow Jones Newswires

March 25, 2009 13:17 ET (17:17 GMT)